It is anticipated that an increasing number of patients undergoing surgical procedures will be taking new anticoagulants and antiaggregants. Currently, only a small amount of data (which were derived from subgroup analyses of undedicated studies) exist regarding the optimal strategy in these patients. Clinical studies are urgently required to establish safe surgical procedures for this high risk patient population. Unlike warfarin, dabigatran and rivaroxaban have predictable and consistent anticoagulant effects with a rapid onset of action, short half-life, and consequently no need for routine laboratory testing. The pharmacologic profiles of these drugs represent an advantage for patients on chronic oral anticoagulant treatment who are undergoing invasive procedures. These drugs may minimize patient time spent without the antithrombotic effects of oral anticoagulants during the perioperative period, potentially eliminating the need for bridging therapy altogether. © 2012 Türk Kardiyoloji Derneǧi.